Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventricle

G E Newton1, A B Parker, J S Landzberg

  • 1Cardiovascular Division, Department of Medicine, Mount Sinai Hospital, the University of Toronto, Ontario, Canada.

Insights

Muscarinic receptor stimulation negatively impacts heart failure by slowing relaxation and reducing beta-adrenergic responses. This study reveals key insights into cardiac function modulation in heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Heart failure is characterized by impaired left ventricular function.
  • Beta-adrenergic stimulation typically enhances contractility but can be less effective in heart failure.
  • The role of muscarinic receptors in modulating cardiac function during heart failure requires further elucidation.

Purpose of the Study:

  • To investigate the impact of muscarinic receptor modulation on left ventricular function.
  • To assess the interaction between muscarinic and beta-adrenergic pathways in normal and failing hearts.
  • To determine the specific effects of acetylcholine and atropine on cardiac contractility and relaxation.

Main Methods:

  • Intracoronary administration of acetylcholine and atropine in patients with heart failure and healthy controls.
  • Measurement of left ventricular +dP/dt (contractility) and isovolumic relaxation time (Tau).
  • Evaluation of responses to dobutamine (a beta-adrenergic agonist) alone and in combination with muscarinic agents.

Main Results:

  • Acetylcholine inhibited dobutamine-induced contractility in both normal and heart failure groups.
  • Acetylcholine prolonged isovolumic relaxation time (negative lusitropic effect) in heart failure patients.
  • Atropine partially reversed acetylcholine's effects, indicating muscarinic receptor involvement.

Conclusions:

  • Muscarinic receptor stimulation exerts an independent negative lusitropic effect on the failing human left ventricle.
  • Muscarinic stimulation antagonizes the beneficial effects of beta-adrenergic stimulation in heart failure.
  • Targeting muscarinic pathways may offer novel therapeutic strategies for heart failure management.

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...